Ringwald P, Le Bras J, Havermann K, Flachs H
Centre national de référence de la chimio-sensibilité du paludisme, Paris, France.
Bull Soc Pathol Exot Filiales. 1989 Jan;82(1):124-9.
Seventy-nine French residents in Dar-es-Salaam, Tanzania, on 3 chemoprophylactic regimens, were included in a prospective study for a mean time of 10.8 +/- 3 months. No malaria attack was observed in the group (n = 32) taking chlorproguanil and chloroquine for chemoprophylaxis. Two attacks were reported in the group (n = 29) using chlorproguanil alone and 5 attacks in the group (n = 20) that was not taking antimalarial chemoprophylaxis. The blood concentration of chlorproguanil and chlorcycloguanil, the active metabolite, were measured, 3 hours (II3), 3 days (D3), and 7 days (D7) after the weekly dose. The urine concentration was measured at D7. The prophylaxis failure with chlorproguanil can be explained either by irregular use of the drug, or insufficiently lasting plasma concentration of chlorcyloguanil, or existence of parasite resistance to dihydrofolate reductase inhibitors.
79名在坦桑尼亚达累斯萨拉姆的法国居民采用3种化学预防方案,被纳入一项前瞻性研究,平均时间为10.8±3个月。接受氯胍和氯喹进行化学预防的组(n = 32)未观察到疟疾发作。单独使用氯胍的组(n = 29)报告有2例发作,未进行抗疟化学预防的组(n = 20)有5例发作。在每周给药后3小时(II3)、3天(D3)和7天(D7)测量氯胍和活性代谢物氯环胍的血药浓度。在D7测量尿药浓度。氯胍预防失败的原因可能是药物使用不规律、氯环胍血浆浓度持续时间不足或寄生虫对二氢叶酸还原酶抑制剂产生耐药性。